23 completed, 6 unknown, 4 terminated, 3 withdrawn. 38 Phase 2, 11 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 38 | Completed 23, Unknown 6, Terminated 4, Withdrawn 3, Recruiting 1, Suspended 1 |
| Phase 3 | 11 | Completed 8, Unknown 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Duodenal Diseases: new trials by email Literature Review of Duodenal Diseases trials Research Report on Duodenal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine - Gastrointestinal Carcinoma, Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-09-09 | 2025-09-11 | |
| Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy Bupivacaine, Hydromorphone, Iopamidol - Duodenal Neoplasm, Pancreatic Neoplasm | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 78 | 2023-11-10 | 2026-02-03 |
| Testing Obeticholic Acid for Familial Adenomatous Polyposis Biopsy Procedure, Biospecimen Collection, Gastrointestinal Endoscopy - Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2023-01-19 | 2026-05-14 |
| A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis Anaprazole sodium 40 mg, Anaprazole sodium 60 mg, Rabeprazole sodium 20 mg - Reflux Esophagitis, Gastroesophageal Reflux | Phase 2 | Unknown | Xuanzhu Biopharmaceutical Co., Ltd. | 156 | 2022-12-01 | 2022-11-03 |
| Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy Placebo, Pantoprazole - Pancreatic Cancer, Pancreas Cancer | Phase 2 | Terminated | Washington University School of Medicine | 56 | 2022-04-21 | 2025-05-06 |
| Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy Stereotactic radiotherapy - Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 33 | 2020-12-01 | 2022-12-07 |
| Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis X842, X842 Placebo, Lansoprazole - Reflux Esophagitis | Phase 2 | Completed | Jiangsu Sinorda Biomedicine Co., Ltd | 90 | 2020-01-21 | 2025-07-17 |
| To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects ATB-346 OR Placebo, Naproxen sodium - Gastric Ulcer | Phase 1 / Phase 2 | Completed | Antibe Therapeutics Inc. | 258 | 2017-09-08 | 2018-06-06 |
| A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism Rivaroxaban, Dalteparin, apixaban - Cancer-associated Thrombosis, Esophageal Cancer | Phase 2 | Unknown | Asan Medical Center | 176 | 2017-08-07 | 2020-01-06 |
| Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis Proton-pump inhibitor, Propranolol+Proton-pump inhibitor - Liver Cirrhosis, Peptic Ulcer | Phase 2 / Phase 3 | Terminated | Taipei Veterans General Hospital, Taiwan | 10 | 2016-12-26 | 2020-06-23 |
| Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Deferiprone, Acetylcysteine, Sitagliptin and Metformin - Diabetes Mellitus, Iron Metabolism Disorders | Phase 2 / Phase 3 | Unknown | Hadassah Medical Organization | 20 | 2016-12-01 | 2016-08-29 |
| To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis Z-215 10mg, Z-215 20mg, Z-215 Placebo - Esophagitis, Reflux | Phase 2 | Completed | Zeria Pharmaceutical | 503 | 2015-05-01 | 2017-07-02 |
| Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users Placebo, PMK-S005 1, PMK-S005 2 - Peptic Ulcer | Phase 2 | Completed | PharmaKing | 88 | 2014-11-24 | 2018-01-23 |
| Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT Repamipide, Placebo - Gastric Ulcer Induced by Anti-platelet Agent, Duodenal Ulcer Induced by Anti-platelet Agent | Phase 2 / Phase 3 | Completed | King Chulalongkorn Memorial Hospital | 142 | 2014-07-01 | 2019-02-27 |
| Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy Lanreotide - Acid Reflux Esophagitis, Non-acid Reflux Esophagitis | Phase 2 | Unknown | Universitair Ziekenhuis Brussel | 10 | 2014-04-01 | 2014-02-04 |
| Residual Gastric Volume After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein Carbohydrate plus whey protein enriched drink - Peptic Ulcer, Gastritis | Phase 2 / Phase 3 | Completed | Federal University of Mato Grosso | 30 | 2013-02-01 | 2013-04-10 |
| Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis Esomeprazole 40mg, YH4808 A mg, YH4808 B mg - Reflux Esophagitis | Phase 2 | Completed | Yuhan Corporation | 154 | 2012-12-01 | 2014-07-10 |
| Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers SQ109 - Helicobacter Pylori Infection | Phase 2 | Withdrawn | Sequella, Inc. | 2012-03-01 | 2015-11-17 | |
| Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) Rabeprazole - Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 405 | 2011-12-01 | 2015-12-21 |
| Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) E3810, Teprenone - Gastric or Duodenal Ulcers Caused by Low-dose Aspirin | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 472 | 2011-07-01 | 2014-11-26 |
Showing 20 of 38. Sign in to see all of them.
Duodenal Neoplasms (8) · Peptic Ulcer (8) · Stomach Ulcer (8) · Esophagitis, Peptic (7) · Pancreatic Neoplasms (7) · Duodenal Ulcer (6) · Zollinger-Ellison Syndrome (6) · Gastrinoma (3) · Gastroesophageal Reflux (3) · Adenoma, Islet Cell (2) · Adenomatous Polyposis Coli (2) · Biliary Tract Neoplasms (2) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Gastritis (2)
Digestive System Diseases (37) · Intestinal Diseases (37) · Gastrointestinal Diseases (36) · Stomach Diseases (31) · Peptic Ulcer (22) · Digestive System Neoplasms (14) · Gastrointestinal Neoplasms (14) · Neoplasms by Site (14) · Neoplasms (13) · Endocrine System Diseases (12) · Endocrine Gland Neoplasms (11) · Pancreatic Diseases (11) · Gastroenteritis (9) · Neoplasms by Histologic Type (9)
Rabeprazole (7) · Esomeprazole (2) · Naproxen (2) · Omeprazole (2) · Pantoprazole (2) · ilaprazole (2) · 2-(6-methoxy-napthalen-2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester (1) · Acetylcysteine (1) · Amoxicillin (1) · Biopsy (1) · Bupivacaine (1) · Capecitabine (1) · Carbohydrates (1) · Celecoxib (1) · Clarithromycin (1)
Eisai Co., Ltd. (3) · National Cancer Institute (NCI) (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Hamamatsu University (2) · Livzon Pharmaceutical Group Inc. (2) · Antibe Therapeutics Inc. (1) · Asan Medical Center (1) · Columbia University (1) · Erasmus Medical Center (1) · Federal University of Mato Grosso (1) · Hadassah Medical Organization (1) · Jiangsu Sinorda Biomedicine Co., Ltd (1) · Kaohsiung Veterans General Hospital. (1) · Karolinska Institutet (1) · King Chulalongkorn Memorial Hospital (1)
United States (10) · Japan (6) · China (3) · South Korea (3) · Belgium (2) · Canada (2) · Netherlands (2) · Taiwan (2) · Brazil (1) · France (1) · Greece (1) · Hungary (1) · Israel (1) · Poland (1) · Puerto Rico (1)
Nobuyuki Sugisaki (2) · Alan Thomson, MD, Prof. (1) · Bjorn WH van Heumen, MD (1) · David Zangen, Professor (1) · Deepen Patel, MD (1) · Eduardo Vilar-Sanchez (1) · Ellen Kampman, Ph D (1) · Farshad Frozanpor (1) · Fokko M Nagengast, MD, Ph D (1) · Frank Lanza, MD (1) · James Flaherty (1) · James Yao (1) · Jay L Goldstein, MD (1) · Kim Moubax, Assistent (1)
PMID 20679904, PMID 21144850, PMID 23919274, PMID 24245549, PMID 25956795, PMID 30919492, PMID 34172290, PMID 38910891, PMID 39317507, PMID 39836012
P30CA016672 (2), N01CM62202 (1), P30CA077598 (1), U01CA062490 (1), UG1CA242609 (1)